-Continue to advance Friedreich’s Ataxia and advance one other program into lead optimization in 2024. --In large animal studies, establish adeno-associated virus (AAV) delivery platform and route of administration for neuromuscular programs in 2024.
Friday, March 1, 2024
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updat
CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.
